We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · June 22, 2022

Dimethyl Fumarate Is Associated With Lower Rates of Infection and Infection-Related Health Care Costs Than Ocrelizumab

Multiple Sclerosis and Related Disorders


Additional Info

Disclosure statements are available on the authors' profiles:

Multiple Sclerosis and Related Disorders
Dimethyl fumarate is associated with lower rates of infection and lower infection-related healthcare costs when compared with ocrelizumab
Mult Scler Relat Disord 2022 Jun 02;[EPub Ahead of Print], JA Nicholas, M Gudesblatt, M Garabedian, et al

Further Reading